FDA Priority Review Boosts Replimune's Prospects Replimune Group's RP1, an oncolytic immunotherapy targeting advanced melanoma, has received FDA priority review, with a PDUFA date set for July 22, 2025. Analysts are optimistic, projecting a potential commercial launch later this year. The development highlights Replimune's pivotal role in addressing unmet needs in oncology and its growth potential.123